Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our finding that MYC directly deregulates the expression of TET1 and TET2 in T-ALL provides novel evidence that MYC controls DNA (hydroxy)methylation in a genome-wide fashion.
|
31266538 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As the only robust zebrafish pre-B ALL model and only example where T-ALL also develops, this model can reveal differences between MYC-driven pre-B vs. T-ALL and be exploited to discover novel pre-B ALL therapies.
|
30111845 |
2019 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Allelic loss of ufd1 in zebrafish induces tumor cell apoptosis and impairs MYC-driven T-ALL progression but does not affect general health.
|
29743725 |
2018 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MYC overexpression significantly rescues T-ALL cell death resulted from SHQ1 inactivation.
|
30323192 |
2018 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
As result, the oncogenic activity of NOTCH1 in T-ALL is strictly dependent on MYC upregulation, which makes the NOTCH1-MYC regulatory circuit an attractive therapeutic target for the treatment of T-ALL.
|
28115368 |
2017 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Notch is a major oncogenic driver in T cell acute lymphoblastic leukemia (T-ALL), in part because it binds to an enhancer that increases expression of MYC.
|
29023469 |
2017 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Hence, shRNA-mediated knock-down of endogenous MYC in human T-ALL and Burkitt's lymphoma cell lines downregulated DNMT3B expression.
|
29100357 |
2017 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, the activity of the miR-30a-NOTCH-MYC loop was validated in primary DLBCL and T-ALL samples.
|
25311243 |
2015 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of c-MYC is observed in both Acute Myeloid Leukemia (AML) and T-cell Acute Lymphoblastic Leukemia (T-ALL).
|
26517351 |
2015 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together these results identify N-Me as a long-range oncogenic enhancer implicated directly in the pathogenesis of human leukemia and highlight the importance of the NOTCH1-MYC regulatory axis in T cell transformation and as a therapeutic target in T-ALL.
|
25194570 |
2014 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Genetic profile of T-cell acute lymphoblastic leukemias with MYC translocations.
|
25270907 |
2014 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Consistent with its anti-LIC activity in mice, treatment with the BET bromodomain BRD4 inhibitor JQ1 reduces C-MYC expression and inhibits the growth of relapsed and IF pediatric T-ALL samples in vitro.
|
24394663 |
2014 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, to determine the relevance of this observation in human pathogenesis we analyzed a human T-ALL case at diagnosis and relapse using the molecular stigmata of V(D)J recombination as markers of malignant progression; we similarly demonstrate that despite the occurrence of TAL1 and MYC translocations in early thymocyte ontogeny, subsequent oncogenic alterations were required to drive oncogenesis.
|
24249258 |
2014 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The most common recurrent cytogenetic abnormalities in T-lymphoblastic leukemia (T-acute lymphoblastic leukemia [T-ALL]) involve T-cell receptor (TCR) loci and a variety of partner genes, including HOX11, HOX11L2, MYC, and TAL1.
|
22563559 |
2012 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Altogether, our data lend further support to the significance of therapeutic targeting of MYC and/or the PTEN/AKT pathways, both in GSI-resistant and identified NOTCH1-independent/MYC-mediated T-ALL patients.
|
21527520 |
2011 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we report that NOTCH(IC) is able to maintain T-ALL tumors formed in the presence of exogenous NOTCH(IC) and c-MYC when exogenous c-MYC expression is extinguished.
|
21217079 |
2011 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, after prolonged inactivation of MYC in a conditional transgenic mouse model of Eμ-tTA/tetO-MYC T-cell acute lymphoblastic leukemia, some of the tumors recur, recapitulating what is frequently observed in human tumors in response to targeted therapies.
|
21969595 |
2011 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Results of the present study revealed that miR-196b becomes non-functional in T-cell ALL as a consequence of mutations in 3'-UTR of c-myc gene in T-cell ALL cellular models.
|
20924650 |
2011 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Thus, miR-451 and miR-709 function as potent suppressors of oncogenesis in NOTCH1-induced mouse T-ALL, and miR-451 influences MYC expression in human T-ALL bearing NOTCH1 mutations.
|
21464222 |
2011 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We found that TLX1 and NOTCH synergistically regulate transcription in T-ALL, at least in part via the sharing of a TLE corepressor and by augmenting expression of MYC.
|
20618946 |
2010 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The overall patterns of NOTCH1-mediated gene expression in human and mouse T-ALLs were remarkably similar, as defined early in transformation in the mouse by the regulation of MYC and its target genes and activation of nuclear factor-kappaB and PI3K/AKT pathways.
|
20007543 |
2010 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas.
|
18765521 |
2008 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Most of these resistant lines also failed to down-regulate the mRNA levels of the NOTCH targets MYC and DELTEX1 after treatment with MRK-003, implying that residual NOTCH signaling in T-ALLs with FBW7 mutations contributes to GSI resistance.
|
17646409 |
2007 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The MOLT-16 cell line was established from the leukemic cells of a patient with T-cell acute lymphoblastic leukemia and contains a t(8;14)(q24;q11) resulting in juxtaposition of sequences downstream of the MYC gene on chromosome 8 and the J region of the T-cell receptor alpha chain gene (TCRA) on chromosome 14.
|
9408752 |
1997 |
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.400 |
FusionGene
|
disease |
ORPHANET |
|
|
|